Technical Analysis for QNCX - Quince Therapeutics, Inc.

Grade Last Price % Change Price Change
C 1.96 -5.77% -0.12
QNCX closed down 5.77 percent on Friday, November 22, 2024, on 1.64 times normal volume. The bulls were able to push the stock to a new 52-week high.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Extremely Strong Up Up Up

Date Alert Name Type % Chg
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Parabolic Rise Strength 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -5.77%
New 52 Week High Strength -5.77%
Wide Bands Range Expansion -5.77%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 13 hours ago
Outside Day about 13 hours ago
Down 5% about 13 hours ago
Down 3% about 13 hours ago
Fell Below Previous Day's Low about 13 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Quince Therapeutics, Inc. Description

Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Organ Systems Bone Rare Diseases Acute Pain Skeletal Disorders Bone Fracture Skeletal System Musculoskeletal System Osteogenesis Imperfecta

Is QNCX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.45
52 Week Low 0.5116
Average Volume 641,975
200-Day Moving Average 0.96
50-Day Moving Average 1.13
20-Day Moving Average 1.61
10-Day Moving Average 1.80
Average True Range 0.25
RSI (14) 67.53
ADX 76.18
+DI 38.43
-DI 2.36
Chandelier Exit (Long, 3 ATRs) 1.71
Chandelier Exit (Short, 3 ATRs) 1.61
Upper Bollinger Bands 2.13
Lower Bollinger Band 1.10
Percent B (%b) 0.84
BandWidth 63.43
MACD Line 0.24
MACD Signal Line 0.23
MACD Histogram 0.0165
Fundamentals Value
Market Cap 84.02 Million
Num Shares 42.9 Million
EPS -0.76
Price-to-Earnings (P/E) Ratio -2.58
Price-to-Sales 0.00
Price-to-Book 0.67
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.12
Resistance 3 (R3) 3.15 2.80 2.92
Resistance 2 (R2) 2.80 2.51 2.78 2.86
Resistance 1 (R1) 2.38 2.32 2.21 2.35 2.79
Pivot Point 2.03 2.03 1.94 2.01 2.03
Support 1 (S1) 1.61 1.74 1.44 1.58 1.13
Support 2 (S2) 1.26 1.55 1.24 1.06
Support 3 (S3) 0.84 1.26 1.00
Support 4 (S4) 0.81